HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis
Zheng Xiao, Peng Luo, Guoli Li, Huifang Tan, Chen Zhou, Dong Zeng, Yinyin Chen, Ying Li · 2025
Read HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis by Zheng Xiao, Peng Luo, Guoli Li, Huifang Tan, Chen Zhou, Dong Zeng, Yinyin Chen, Ying Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821307.txt.
Description
Zheng Xiao and seven co-authors build a nanoparticle system that delivers a drug straight to the kidney tubules to fight renal interstitial fibrosis, the scarring that drives chronic kidney disease toward failure. A form of cell death called ferroptosis helps drive the scarring. The drug rosiglitazone can block it, but the drug dissolves poorly and spreads through the whole body.
The team loaded rosiglitazone into hollow polydopamine particles, coated them for stability, and added a peptide that homes to kidney tubule cells. The particles lingered in scarred kidneys and were well tolerated. In cell and animal tests, they curbed ferroptosis in three ways at once: lowering a key enzyme, mopping up iron, and clearing reactive oxygen. They also protected mitochondria and calmed inflammation, easing the scarring. The authors present the platform as a step toward targeted kidney therapy.
Catalog record
| CREATOR | Zheng Xiao, Peng Luo, Guoli Li, Huifang Tan, Chen Zhou, Dong Zeng, Yinyin Chen, Ying Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |